%0 Journal Article %A Miao Li-na %A Du Jian-peng %A Guo Ming %A Chen Zhu-hong %A Qu Hua %A Shi Da-zhuo %T Prognostic value of the level of gut microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: a meta-analysis and systematic review %D 2021 %R 10.1101/2021.05.04.21256606 %J medRxiv %P 2021.05.04.21256606 %X Aims Intestinal microbial metabolite trimethylamine N-oxide (TMAO) is considered to be a key mediator between intestinal microbiota changes and heart failure (HF). Clinical evidences showed that patients with HF had relatively high level of plasma TMAO than those without. However, the relationship between plasma TMAO and the prognostics of patients with HF has not been investigated. This study aims to evaluate the relationship between plasma TMAO and the outcomes of patients with HF.Methods and results PubMed, EMBASE, Cochrane Library databases were included for systematic literature search. The included studies were used for the extraction of overall hazard ratios of adverse events data (myocardial infarction, cardiovascular hospitalization, cardiovascular mortality, revascularization and stroke) as well as all‐cause mortality data. Cochran’s Q test and I2 statistical methods were applied to assess heterogeneity. Selection of random effects model or fixed effects model were according to heterogeneity. Sensitivity analysis and subgroup analysis were used to find the source of heterogeneity. Among the 7 included studies, all studies published all‐cause mortality data and 6 provided adverse events. And the results demonstrated that higher level of plasma TMAO (defined according to original studies)was an indicator of risk of all‐cause mortality (HR =0.26, 95% CI: 0.20-0.32, I2 = 96.1%,) and risk of adverse events (HR =1.79, 95% CI: 1.37-2.22, I2 = 78.6%). There was no significant publication bias among the included studies (Egger’s,P = 0.130;Begg’s tests P = 0.452). Further subgroup analysis did not show that study location, follow-up time, or year of publication had any effect on the results. The results of sensitivity analysis do not indicate that any of the included affected the robustness of the results.Conclusion Heart failure patients with higher baseline plasma TMAO is a risk factor for all-cause mortality and adverse events.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by Youth talent promoyion project of Chinese society of traditional Chinese medicine in 2020-2022(No.2020-QNRCI-02) and the project of National Natural Science Foundation of China (Grant No. 81774141).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a systematic review and meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. %U https://www.medrxiv.org/content/medrxiv/early/2021/05/06/2021.05.04.21256606.full.pdf